Gut microbiota role in irritable bowel syndrome: New therapeutic strategies

World Journal of Gastroenterology

Volumn 22, Issue 7, 2016, Pages 2219-2241

  Distrutti, Eleonora ^a   Monaldi, Lorenzo ^a   Ricci, Patrizia ^b   Fiorucci, Stefano ^b  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Antibiotics; Fecal transplantation; Gut microbiota; Irritable bowel syndrome; Prebiotics; Probiotics; Synbiotics

Indexed keywords

ANTIBIOTIC AGENT; PATTERN RECOGNITION RECEPTOR; PREBIOTIC AGENT; PROBIOTIC AGENT; SYNBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; AUTONOMIC NERVOUS SYSTEM; BRAIN DYSFUNCTION; COLON MOTILITY; CONCEPTUAL FRAMEWORK; DISTRESS SYNDROME; DRUG EFFICACY; DRUG SAFETY; ECOSYSTEM; ENTERITIS; FECAL MICROBIOTA TRANSPLANTATION; GASTROINTESTINAL MOTILITY DISORDER; GENE EXPRESSION; HUMAN; HYPERSENSITIVITY; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOREACTIVITY; INTESTINE FLORA; INTESTINE INNERVATION; INTESTINE MOTILITY; IRRITABLE COLON; NONHUMAN; REVIEW; ANIMAL; BACTERIUM; GROWTH, DEVELOPMENT AND AGING; HOST PATHOGEN INTERACTION; INTESTINE; IRRITABLE BOWEL SYNDROME; MICROBIOLOGY; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; FECAL MICROBIOTA TRANSPLANTATION; GASTROINTESTINAL MICROBIOME; HOST-PATHOGEN INTERACTIONS; HUMANS; INTESTINES; IRRITABLE BOWEL SYNDROME; PREBIOTICS; PROBIOTICS; SYNBIOTICS; TREATMENT OUTCOME;

EID: 84959872636     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i7.2219     Document Type: Review

References (311)

1. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999; 45 Suppl 2: II43-II47 [PMID: 10457044]
2. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-1491 [PMID: 16678561 DOI: 10.1136/gut.45.2008.ii43]
3. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712-721.e4 [PMID: 22426087 DOI: 10.1016/j.cgh.2012.02.029]
4. Simrén M, Svedlund J, Posserud I, Björnsson ES, Abrahamsson H. Health-related quality of life in patients attenDing a gastroenterology outpatient clinic: functional disorders versus organic diseases. Clin Gastroenterol Hepatol 2006; 4: 187-195 [PMID: 16469679 DOI: 10.1016/S1542-3565(05)00981-X]
5. Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994; 107: 271-293 [PMID: 8020671]
6. Distrutti E, Salvioli B, Azpiroz F, Malagelada JR. Rectal function and bowel habit in irritable bowel syndrome. Am J Gastroenterol 2004; 99: 131-137 [PMID: 14687154]
7. De Giorgio R, Barbara G. Is irritable bowel syndrome an inflammatory disorder? Curr Gastroenterol Rep 2008; 10: 385-390 [PMID: 18627650]
8. Kiank C, Taché Y, Larauche M. Stress-related modulation of inflammation in experimental models of bowel disease and postinfectious irritable bowel syndrome: role of corticotropin-releasing factor receptors. Brain Behav Immun 2010; 24: 41-48 [PMID: 19698778 DOI: 10.1016/j.bbi.2009.08.006]
9. Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012; 303: G775-G785 [PMID: 22837345 DOI: 10.1152/ajpgi.00155.2012]
10. Savage DC. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol 1977; 31: 107-133 [PMID: 334036]
11. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Doré J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J, Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464: 59-65 [PMID: 20203603 DOI: 10.1038/nature08821]
12. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 2004; 431: 931-945 [PMID: 15496913 DOI: 10.1038/nature03001]
13. Murgas Torrazza R, Neu J. The developing intestinal microbiome and its relationship to health and disease in the neonate. J Perinatol 2011; 31 Suppl 1: S29-S34 [PMID: 21448201 DOI: 10.1038/jp.2010.172]
14. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006; 444: 1022-1023 [PMID: 17183309 DOI: 10.1038/4441022a]
15. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006; 444: 1027-1031 [PMID: 17183312 DOI: 10.1038/nature05414]
16. Round JL, Lee SM, Li J, Tran G, Jabri B, Chatila TA, Mazmanian SK. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 2011; 332: 974-977 [PMID: 21512004 DOI: 10.1126/science.1206095]
17. Ivanov II, Atarashi K, Manel N, Brodie EL, Shima T, Karaoz U, Wei D, Goldfarb KC, Santee CA, Lynch SV, Tanoue T, Imaoka A, Itoh K, Takeda K, Umesaki Y, Honda K, Littman DR. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009; 139: 485-498 [PMID: 19836068 DOI: 10.1016/j.cell.2009.09.033]
18. Ivanov II, Frutos Rde L, Manel N, Yoshinaga K, Rifkin DB, Sartor RB, Finlay BB, Littman DR. Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe 2008; 4: 337-349 [PMID: 18854238 DOI: 10.1016/j.chom.2008.09.009]
19. Candela M, Perna F, Carnevali P, Vitali B, Ciati R, Gionchetti P, Rizzello F, Campieri M, Brigidi P. Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production. Int J Food Microbiol 2008; 125: 286-292 [PMID: 18524406 DOI: 10.1016/j.ijfoodmicro.2008.04.012]
20. Fukuda S, Toh H, Hase K, Oshima K, Nakanishi Y, Yoshimura K, Tobe T, Clarke JM, Topping DL, Suzuki T, Taylor TD, Itoh K, Kikuchi J, Morita H, Hattori M, Ohno H. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 2011; 469: 543-547 [PMID: 21270894 DOI: 10.1038/nature09646]
21. Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, Peters EC, Siuzdak G. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci USA 2009; 106: 3698-3703 [PMID: 19234110 DOI: 10.1073/pnas.0812874106]
22. Antunes LC, Han J, Ferreira RB, Loli? P, Borchers CH, Finlay BB. Effect of antibiotic treatment on the intestinal metabolome. Antimicrob Agents Chemother 2011; 55: 1494-1503 [PMID: 21282433 DOI: 10.1128/AAC.01664-10]
23. Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature 2012; 489: 242-249 [PMID: 22972297 DOI: 10.1002/jbmr.1588]
24. Nicholson JK, Holmes E, Kinross J, Burcelin R, Gibson G, Jia W, Pettersson S. Host-gut microbiota metabolic interactions. Science 2012; 336: 1262-1267 [PMID: 22674330 DOI: 10.1126/science.1223813]
25. Marcobal A, Kashyap PC, Nelson TA, Aronov PA, Donia MS, Spormann A, Fischbach MA, Sonnenburg JL. A metabolomic view of how the human gut microbiota impacts the host metabolome using humanized and gnotobiotic mice. ISME J 2013; 7: 1933-1943 [PMID: 23739052]
26. Matsumoto M, Kibe R, Ooga T, Aiba Y, Sawaki E, Koga Y, Benno Y. Cerebral low-molecular metabolites influenced by intestinal microbiota: a pilot study. Front Syst Neurosci 2013; 7: 9 [PMID: 23630473 DOI: 10.3389/fnsys.2013.00009]
27. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 2012; 13: 701-712 [PMID: 22968153 DOI: 10.1038/nrn3346]
28. Lyte M. Probiotics function mechanistically as delivery vehicles for neuroactive compounds: Microbial endocrinology in the design and use of probiotics. Bioessays 2011; 33: 574-581 [PMID: 21732396 DOI: 10.1002/bies.201100024]
29. Forsythe P, Kunze WA. Voices from within: gut microbes and the CNS. Cell Mol Life Sci 2013; 70: 55-69 [PMID: 22638926]
30. Asano Y, Hiramoto T, Nishino R, Aiba Y, Kimura T, Yoshihara K, Koga Y, Sudo N. Critical role of gut microbiota in the production of biologically active, free catecholamines in the gut lumen of mice. Am J Physiol Gastrointest Liver Physiol 2012; 303: G1288-G1295 [PMID: 23064760 DOI: 10.1152/ajpgi.00341.2012]
31. Barrett E, Ross RP, O'Toole PW, Fitzgerald GF, Stanton C. Aminobutyric acid production by culturable bacteria from the human intestine. J Appl Microbiol 2012; 113: 411-417 [PMID: 22612585 DOI: 10.1111/j.1365-2672.2012.05344.x]
32. Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, Dubuquoy C, Merour E, Geboes K, Chamaillard M, Ouwehand A, Leyer G, Carcano D, Colombel JF, Ardid D, Desreumaux P. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 2007; 13: 35-37 [PMID: 17159985 DOI: 10.1038/nm1521]
33. Medani M, Collins D, Docherty NG, Baird AW, O'Connell PR, Winter DC. Emerging role of hydrogen sulfide in colonic physiology and pathophysiology. Inflamm Bowel Dis 2011; 17: 1620-1625 [PMID: 21674719 DOI: 10.1002/ibd.21528]
34. Schemann M, Grundy D. Role of hydrogen sulfide in visceral nociception. Gut 2009; 58: 744-747 [PMID: 19433593 DOI: 10.1136/gut.2008.167858]
35. Distrutti E. Hydrogen sulphide and pain. Inflamm Allergy Drug Targets 2011; 10: 123-132 [PMID: 21275898 DOI: 10.2174/18715 2811794776240]
36. Distrutti E, Cipriani S, Renga B, Mencarelli A, Migliorati M, Cianetti S, Fiorucci S. Hydrogen sulphide induces micro opioid receptor-dependent analgesia in a rodent model of visceral pain. Mol Pain 2010; 6: 36 [PMID: 20540729 DOI: 10.1186/1744-8069-6-36]
37. Distrutti E, Sediari L, Mencarelli A, Renga B, Orlandi S, Antonelli E, Roviezzo F, Morelli A, Cirino G, Wallace JL, Fiorucci S. Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels. J Pharmacol Exp Ther 2006; 316: 325-335 [PMID: 16192316 DOI: 10.1124/jpet.105.091595]
38. Dlugosz A, Winckler B, Lundin E, Zakikhany K, Sandström G, Ye W, Engstrand L, Lindberg G. No difference in small bowel microbiota between patients with irritable bowel syndrome and healthy controls. Sci Rep 2015; 5: 8508 [PMID: 25687743 DOI: 10.1038/srep08508]
39. Balsari A, Ceccarelli A, Dubini F, Fesce E, Poli G. The fecal microbial population in the irritable bowel syndrome. Microbiologica 1982; 5: 185-194 [PMID: 7121297]
40. Si JM, Yu YC, Fan YJ, Chen SJ. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol 2004; 10: 1802-1805 [PMID: 15188510 DOI: 10.3748/wjg.v10.i12.1802]
41. Malinen E, Rinttilä T, Kajander K, Mättö J, Kassinen A, Krogius L, Saarela M, Korpela R, Palva A. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005; 100: 373-382 [PMID: 15667495 DOI: 10.1111/j.1572-0241.2005.40312.x]
42. Mättö J, Maunuksela L, Kajander K, Palva A, Korpela R, Kassinen A, Saarela M. Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome-a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol 2005; 43: 213-222 [PMID: 15747442]
43. Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol 2005; 43: 3380-3389 [PMID: 16000463 DOI: 10.1128/JCM.43.7.3380-3389.2005]
44. Maukonen J, Satokari R, Mättö J, Söderlund H, Mattila-Sandholm T, Saarela M. Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant faecal bacteria. J Med Microbiol 2006; 55: 625-633 [PMID: 16585652 DOI: 10.1099/jmm.0.46134-0]
45. Kassinen A, Krogius-Kurikka L, Mäkivuokko H, Rinttilä T, Paulin L, Corander J, Malinen E, Apajalahti J, Palva A. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007; 133: 24-33 [PMID: 17631127 DOI: 10.1053/j.gastro.2007.04.005]
46. Lyra A, Rinttilä T, Nikkilä J, Krogius-Kurikka L, Kajander K, Malinen E, Mättö J, Mäkelä L, Palva A. Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification. World J Gastroenterol 2009; 15: 5936-5945 [PMID: 20014457 DOI: 10.3748/wjg.15.5936]
47. Krogius-Kurikka L, Lyra A, Malinen E, Aarnikunnas J, Tuimala J, Paulin L, Mäkivuokko H, Kajander K, Palva A. Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol 2009; 9: 95 [PMID: 20015409 DOI: 10.1186/1471-230X-9-95]
48. Kerckhoffs AP, Samsom M, van der Rest ME, de Vogel J, Knol J, Ben-Amor K, Akkermans LM. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol 2009; 15: 2887-2892 [PMID: 19533811 DOI: 10.3748/wjg.15.2887]
49. Carroll IM, Ringel-Kulka T, Siddle JP, Klaenhammer TR, Ringel Y. Characterization of the fecal microbiota using high-throughput sequencing reveals a stable microbial community during storage. PLoS One 2012; 7: e46953 [PMID: 23071673 DOI: 10.1371/journal. pone.0046953]
50. Salonen A, de Vos WM, Palva A. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. Microbiology 2010; 156: 3205-3215 [PMID: 20705664 DOI: 10.1099/mic.0.043257-0]
51. Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 2010; 22: 512-519, e114-e115 [PMID: 19903265 DOI: 10.1111/j.1365-2982.2009.01427.x]
52. Carroll IM, Chang YH, Park J, Sartor RB, Ringel Y. Luminal and mucosal-associated intestinal microbiota in patients with diarrheapredominant irritable bowel syndrome. Gut Pathog 2010; 2: 19 [PMID: 21143915 DOI: 10.1186/1757-4749-2-19]
53. Codling C, O'Mahony L, Shanahan F, Quigley EM, Marchesi JR. A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci 2010; 55: 392-397 [PMID: 19693670 DOI: 10.1007/s10620-009-0934-x]
54. Ponnusamy K, Choi JN, Kim J, Lee SY, Lee CH. Microbial community and metabolomic comparison of irritable bowel syndrome faeces. J Med Microbiol 2011; 60: 817-827 [PMID: 21330412 DOI: 10.1099/jmm.0.028126-0]
55. Kerckhoffs AP, Ben-Amor K, Samsom M, van der Rest ME, de Vogel J, Knol J, Akkermans LM. Molecular analysis of faecal and duodenal samples reveals significantly higher prevalence and numbers of Pseudomonas aeruginosa in irritable bowel syndrome. J Med Microbiol 2011; 60: 236-245 [PMID: 20947663 DOI: 10.1099/jmm.0.022848-0]
56. RajiliStojanovi? M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, de Vos WM. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 2011; 141: 1792-1801 [PMID: 21820992 DOI: 10.1053/j.gastro.2011.07.043]
57. Carroll IM, Ringel-Kulka T, Keku TO, Chang YH, Packey CD, Sartor RB, Ringel Y. Molecular analysis of the luminal-and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2011; 301: G799-G807 [PMID: 21737778 DOI: 10.1152/ajpgi.00154.2011]
58. Carroll IM, Ringel-Kulka T, Siddle JP, Ringel Y. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2012; 24: 521-530, e248 [PMID: 22339879 DOI: 10.1111/j.1365-2982.2012.01891.x]
59. Parkes GC, Rayment NB, Hudspith BN, Petrovska L, Lomer MC, Brostoff J, Whelan K, Sanderson JD. Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome. Neurogastroenterol Motil 2012; 24: 31-39 [PMID: 22070725 DOI: 10.1111/j.1365-2982.2011.01803.x]
60. Jeffery IB, O'Toole PW, Öhman L, Claesson MJ, Deane J, Quigley EM, Simrén M. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 2012; 61: 997-1006 [PMID: 22180058 DOI: 10.1136/gutjnl-2011-301501]
61. Chassard C, Dapoigny M, Scott KP, Crouzet L, Del'homme C, Marquet P, Martin JC, Pickering G, Ardid D, Eschalier A, Dubray C, Flint HJ, Bernalier-Donadille A. Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. Aliment Pharmacol Ther 2012; 35: 828-838 [PMID: 22315951 DOI: 10.1111/j.1365-2036.2012.05007.x]
62. König J, Brummer RJ. Alteration of the intestinal microbiota as a cause of and a potential therapeutic option in irritable bowel syndrome. Benef Microbes 2014; 5: 247-261 [PMID: 24583610 DOI: 10.3920/BM2013.0033]
63. Sundin J, Rangel I, Fuentes S, Heikamp-de Jong I, Hultgren-Hörnquist E, de Vos WM, Brummer RJ. Altered faecal and mucosal microbial composition in post-infectious irritable bowel syndrome patients correlates with mucosal lymphocyte phenotypes and psychological distress. Aliment Pharmacol Ther 2015; 41: 342-351 [PMID: 25521822 DOI: 10.1111/apt.13055]
64. Simrén M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 2013; 62: 159-176 [PMID: 22730468 DOI: 10.1136/gutjnl-2012-302167]
65. Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, Neal KR. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47: 804-811 [PMID: 11076879 DOI: 10.1136/gut.47.6.804]
66. Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, Wilson I. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778-1783 [PMID: 12055584 DOI: 10.1053/gast.2002.33579]
67. Guilarte M, Santos J, de Torres I, Alonso C, Vicario M, Ramos L, Martínez C, Casellas F, Saperas E, Malagelada JR. Diarrhoeapredominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 2007; 56: 203-209 [PMID: 17005763]
68. O'Sullivan M, Clayton N, Breslin NP, Harman I, Bountra C, McLaren A, O'Morain CA. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Motil 2000; 12: 449-457 [PMID: 11012945 DOI: 10.1046/j.1365-2982.2000.00221.x]
69. Weston AP, Biddle WL, Bhatia PS, Miner PB. Terminal ileal mucosal mast cells in irritable bowel syndrome. Dig Dis Sci 1993; 38: 1590-1595 [PMID: 8359068]
70. He Q, Wang L, Wang F, Li Q. Role of gut microbiota in a zebrafish model with chemically induced enterocolitis involving toll-like receptor signaling pathways. Zebrafish 2014; 11: 255-264 [PMID: 24758288 DOI: 10.1089/zeb.2013.0917]
71. Walk ST, Blum AM, Ewing SA, Weinstock JV, Young VB. Alteration of the murine gut microbiota during infection with the parasitic helminth Heligmosomoides polygyrus. Inflamm Bowel Dis 2010; 16: 1841-1849 [PMID: 20848461 DOI: 10.1002/ibd.21299]
72. Kuehbacher T, Rehman A, Lepage P, Hellmig S, Fölsch UR, Schreiber S, Ott SJ. Intestinal TM7 bacterial phylogenies in active inflammatory bowel disease. J Med Microbiol 2008; 57: 1569-1576 [PMID: 19018031 DOI: 10.1099/jmm.0.47719-0]
73. Reshef L, Kovacs A, Ofer A, Yahav L, Maharshak N, Keren N, Konikoff FM, Tulchinsky H, Gophna U, Dotan I. Pouch Inflammation Is Associated With a Decrease in Specific Bacterial Taxa. Gastroenterology 2015; 149: 718-727 [PMID: 26026389 DOI: 10.1053/j.gastro.2015.05.041]
74. Machiels K, Sabino J, Vandermosten L, Joossens M, Arijs I, de Bruyn M, Eeckhaut V, Van Assche G, Ferrante M, Verhaegen J, Van Steen K, Van Immerseel F, Huys G, Verbeke K, Wolthuis A, de Buck Van Overstraeten A, D'Hoore A, Rutgeerts P, Vermeire S. Specific members of the predominant gut microbiota predict pouchitis following colectomy and IPAA in UC. Gut 2015; Epub ahead of print [PMID: 26423113 DOI: 10.1136/gutjnl-2015-309398]
75. Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 535-544 [PMID: 17661757]
76. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009; 136: 1979-1988 [PMID: 19457422]
77. Jalanka-Tuovinen J, Salojärvi J, Salonen A, Immonen O, Garsed K, Kelly FM, Zaitoun A, Palva A, Spiller RC, de Vos WM. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut 2014; 63: 1737-1745 [PMID: 24310267]
78. Villarreal AA, Aberger FJ, Benrud R, Gundrum JD. Use of broadspectrum antibiotics and the development of irritable bowel syndrome. WMJ 2012; 111: 17-20 [PMID: 22533211]
79. RajiliStojanovi? M, Jonkers DM, Salonen A, Hanevik K, Raes J, Jalanka J, de Vos WM, Manichanh C, Golic N, Enck P, Philippou E, Iraqi FA, Clarke G, Spiller RC, Penders J. Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena? Am J Gastroenterol 2015; 110: 278-287 [PMID: 25623659]
80. Mayer EA, Knight R, Mazmanian SK, Cryan JF, Tillisch K. Gut microbes and the brain: paradigm shift in neuroscience. J Neurosci 2014; 34: 15490-15496 [PMID: 25392516]
81. Tillisch K, Labus J, Kilpatrick L, Jiang Z, Stains J, Ebrat B, Guyonnet D, Legrain-Raspaud S, Trotin B, Naliboff B, Mayer EA. Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology 2013; 144: 1394-1401, 1401.e1-e4 [PMID: 23474283]
82. Fond G, Loundou A, Hamdani N, Boukouaci W, Dargel A, Oliveira J, Roger M, Tamouza R, Leboyer M, Boyer L. Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci 2014; 264: 651-660 [PMID: 24705634]
83. Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 2009; 29: 508-518 [PMID: 19053980]
84. Kellow JE, Phillips SF. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology 1987; 92: 1885-1893 [PMID: 3569764]
85. Suttor VP, Prott GM, Hansen RD, Kellow JE, Malcolm A. Evidence for pelvic floor dyssynergia in patients with irritable bowel syndrome. Dis Colon Rectum 2010; 53: 156-160 [PMID: 20087090 DOI: 10.1007/DCR.0b013e3181c188e8]
86. Serra J, Villoria A, Azpiroz F, Lobo B, Santos J, Accarino A, Malagelada JR. Impaired intestinal gas propulsion in manometrically proven dysmotility and in irritable bowel syndrome. Neurogastroenterol Motil 2010; 22: 401-406, e91-e92 [PMID: 20047636 DOI: 10.1111/j.1365-2982.2009.01447]
87. Cogliandro RF, Antonucci A, De Giorgio R, Barbara G, Cremon C, Cogliandro L, Frisoni C, Pezzilli R, Morselli-Labate AM, Corinaldesi R, Stanghellini V. Patient-reported outcomes and gut dysmotility in functional gastrointestinal disorders. Neurogastroenterol Motil 2011; 23: 1084-1091 [PMID: 21917083 DOI: 10.1111/j.1365-2982.2011.01783]
88. Lindfors P, Törnblom H, Sadik R, Björnsson ES, Abrahamsson H, Simrén M. Effects on gastrointestinal transit and antroduodenojejunal manometry after gut-directed hypnotherapy in irritable bowel syndrome (IBS). Scand J Gastroenterol 2012; 47: 1480-1487 [PMID: 23094932 DOI: 10.3109/00365521.2012.7339 55]
89. Staumont G, Delvaux M, Fioramonti J, Berry P, Bueno L, Frexinos J. Differences between jejunal myoelectric activity after a meal and during phase 2 of migrating motor complexes in healthy humans. Dig Dis Sci 1992; 37: 1554-1561 [PMID: 1396003]
90. Quigley EM, Donovan JP, Lane MJ, Gallagher TF. Antroduodenal manometry. Usefulness and limitations as an outpatient study. Dig Dis Sci 1992; 37: 20-28 [PMID: 1728526]
91. Kellow JE, Langeluddecke PM, Eckersley GM, Jones MP, Tennant CC. Effects of acute psychologic stress on small-intestinal motility in health and the irritable bowel syndrome. Scand J Gastroenterol 1992; 27: 53-58 [PMID: 1736343]
92. Schmidt T, Hackelsberger N, Widmer R, Meisel C, Pfeiffer A, Kaess H. Ambulatory 24-hour jejunal motility in diarrheapredominant irritable bowel syndrome. Scand J Gastroenterol 1996; 31: 581-589 [PMID: 8789897]
93. Caenepeel P, Janssens J, Vantrappen G, Eyssen H, Coremans G. Interdigestive myoelectric complex in germ-free rats. Dig Dis Sci 1989; 34: 1180-1184 [PMID: 2752868]
94. Collins S, Verdu E, Denou E, Bercik P. The role of pathogenic microbes and commensal bacteria in irritable bowel syndrome. Dig Dis 2009; 27 Suppl 1: 85-89 [PMID: 20203502 DOI: 10.1159/000268126]
95. Husebye E, Hellström PM, Midtvedt T. Intestinal microflora stimulates myoelectric activity of rat small intestine by promoting cyclic initiation and aboral propagation of migrating myoelectric complex. Dig Dis Sci 1994; 39: 946-956 [PMID: 8174436]
96. Husebye E, Hellström PM, Sundler F, Chen J, Midtvedt T. Influence of microbial species on small intestinal myoelectric activity and transit in germ-free rats. Am J Physiol Gastrointest Liver Physiol 2001; 280: G368-G380 [PMID: 11171619]
97. Berg RD. Bacterial translocation from the gastrointestinal tract. Adv Exp Med Biol 1999; 473: 11-30 [PMID: 10659341]
98. Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI. Molecular analysis of commensal host-microbial relationships in the intestine. Science 2001; 291: 881-884 [PMID: 11157169 DOI: 10.1126/science.291.5505.881]
99. Bär F, Von Koschitzky H, Roblick U, Bruch HP, Schulze L, Sonnenborn U, Böttner M, Wedel T. Cell-free supernatants of Escherichia coli Nissle 1917 modulate human colonic motility: evidence from an in vitro organ bath study. Neurogastroenterol Motil 2009; 21: 559-566, e16-e17 [PMID: 19220758 DOI: 10.1111/j.1365-2982.2008.01258.x]
100. Guarino MP, Sessa R, Altomare A, Cocca S, Di Pietro M, Carotti S, Schiavoni G, Alloni R, Emerenziani S, Morini S, Severi C, Cicala M. Human colonic myogenic dysfunction induced by mucosal lipopolysaccharide translocation and oxidative stress. Dig Liver Dis 2013; 45: 1011-1016 [PMID: 23891549 DOI: 10.1016/j.dld.2013.06.001]
101. Guarino MP, Altomare A, Stasi E, Marignani M, Severi C, Alloni R, Dicuonzo G, Morelli L, Coppola R, Cicala M. Effect of acute mucosal exposure to Lactobacillus rhamnosus GG on human colonic smooth muscle cells. J Clin Gastroenterol 2008; 42 Suppl 3 Pt 2: S185-S190 [PMID: 18685510 DOI: 10.1097/MCG.0b013e31817e1cac]
102. Ammoscato F, Scirocco A, Altomare A, Matarrese P, Petitta C, Ascione B, Caronna R, Guarino M, Marignani M, Cicala M, Chirletti P, Malorni W, Severi C. Lactobacillus rhamnosus protects human colonic muscle from pathogen lipopolysaccharide-induced damage. Neurogastroenterol Motil 2013; 25: 984-e777 [PMID: 24118564 DOI: 10.1111/nmo.12232]
103. Kellow JE, Azpiroz F, Delvaux M, Gebhart GF, Mertz HR, Quigley EM, Smout AJ. Applied principles of neurogastroenterology: physiology/motility sensation. Gastroenterology 2006; 130: 1412-1420 [PMID: 16678555 DOI: 10.1053/j.gastro.2005.08.061]
104. Mayer EA. Emerging disease model for functional gastrointestinal disorders. Am J Med 1999; 107: 12S-19S [PMID: 10588168 DOI: 10.1016/S0002-9343(99)00277-6]
105. Grundy D, Al-Chaer ED, Aziz Q, Collins SM, Ke M, Taché Y, Wood JD. Fundamentals of neurogastroenterology: basic science. Gastroenterology 2006; 130: 1391-1411 [PMID: 16678554 DOI: 10.1053/j.gastro.2005.11.060]
106. Feng B, La JH, Schwartz ES, Gebhart GF. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Neural and neuro-immune mechanisms of visceral hypersensitivity in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012; 302: G1085-G1098 [PMID: 22403791 DOI: 10.1152/ajpgi.00542.2011]
107. Ritchie JA, Ardran GM, Truelove SC. Observations on experimentally induced colonic pain. Gut 1972; 13: 841 [PMID: 5087084]
108. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995; 109: 40-52 [PMID: 7797041]
109. Prior A, Maxton DG, Whorwell PJ. Anorectal manometry in irritable bowel syndrome: differences between diarrhoea and constipation predominant subjects. Gut 1990; 31: 458-462 [PMID: 2338274]
110. Zar S, Benson MJ, Kumar D. Rectal afferent hypersensitivity and compliance in irritable bowel syndrome: differences between diarrhoea-predominant and constipation-predominant subgroups. Eur J Gastroenterol Hepatol 2006; 18: 151-158 [PMID: 16394796]
111. Distrutti E, Hauer SK, Fiorucci S, Pensi MO, Morelli A. Intraduodenal lipids increase perception of rectal distension in IBS patients. Gastroenterology 2000; 118: A138 (abs)
112. Caldarella MP, Milano A, Laterza F, Sacco F, Balatsinou C, Lapenna D, Pierdomenico SD, Cuccurullo F, Neri M. Visceral sensitivity and symptoms in patients with constipation-or diarrheapredominant irritable bowel syndrome (IBS): effect of a low-fat intraduodenal infusion. Am J Gastroenterol 2005; 100: 383-389 [PMID: 15667496 DOI: 10.1111/j.1572-0241.2005.40100.x]
113. Silverman DH, Munakata JA, Ennes H, Mandelkern MA, Hoh CK, Mayer EA. Regional cerebral activity in normal and pathological perception of visceral pain. Gastroenterology 1997; 112: 64-72 [PMID: 8978344]
114. Hertig VL, Cain KC, Jarrett ME, Burr RL, Heitkemper MM. Daily stress and gastrointestinal symptoms in women with irritable bowel syndrome. Nurs Res 2007; 56: 399-406 [PMID: 18004186 DOI: 10.1097/01.NNR.0000299855.60053.88]
115. Aguilera M, Cerdà-Cuéllar M, Martínez V. Antibiotic-induced dysbiosis alters host-bacterial interactions and leads to colonic sensory and motor changes in mice. Gut Microbes 2015; 6: 10-23 [PMID: 25531553 DOI: 10.4161/19490976.2014.990790]
116. Aguilera M, Vergara P, Martínez V. Stress and antibiotics alter luminal and wall-adhered microbiota and enhance the local expression of visceral sensory-related systems in mice. Neurogastroenterol Motil 2013; 25: e515-e529 [PMID: 23711047 DOI: 10.1111/nmo.12154]
117. Theodorou V, Ait Belgnaoui A, Agostini S, Eutamene H. Effect of commensals and probiotics on visceral sensitivity and pain in irritable bowel syndrome. Gut Microbes 2014; 5: 430-436 [PMID: 25184834 DOI: 10.4161/gmic.29796]
118. Mao YK, Kasper DL, Wang B, Forsythe P, Bienenstock J, Kunze WA. Bacteroides fragilis polysaccharide A is necessary and sufficient for acute activation of intestinal sensory neurons. Nat Commun 2013; 4: 1465 [PMID: 23403566 DOI: 10.1038/ncomms2478]
119. Kamiya T, Wang L, Forsythe P, Goettsche G, Mao Y, Wang Y, Tougas G, Bienenstock J. Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats. Gut 2006; 55: 191-196 [PMID: 16361309 DOI: 10.1136/gut.2005.070987]
120. Perez-Burgos A, Wang B, Mao YK, Mistry B, McVey Neufeld KA, Bienenstock J, Kunze W. Psychoactive bacteria Lactobacillus rhamnosus (JB-1) elicits rapid frequency facilitation in vagal afferents. Am J Physiol Gastrointest Liver Physiol 2013; 304: G211-G220 [PMID: 23139216 DOI: 10.1152/ajpgi.00128.2012]
121. Perez-Burgos A, Wang L, McVey Neufeld KA, Mao YK, Ahmadzai M, Janssen LJ, Stanisz AM, Bienenstock J, Kunze WA. The TRPV1 channel in rodents is a major target for antinociceptive effect of the probiotic Lactobacillus reuteri DSM 17938. J Physiol 2015; 593: 3943-3957 [PMID: 26084409 DOI: 10.1113/JP270229]
122. Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol 2015; 28: 203-209 [PMID: 25830558]
123. Tsigos C, Chrousos GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res 2002; 53: 865-871 [PMID: 12377295]
124. Rhee SH, Pothoulakis C, Mayer EA. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol 2009; 6: 306-314 [PMID: 19404271 DOI: 10.1038/nrgastro.2009.35]
125. Collins J, Borojevic R, Verdu EF, Huizinga JD, Ratcliffe EM. Intestinal microbiota influence the early postnatal development of the enteric nervous system. Neurogastroenterol Motil 2014; 26: 98-107 [PMID: 24329946 DOI: 10.1111/nmo.12236]
126. Sudo N, Chida Y, Aiba Y, Sonoda J, Oyama N, Yu XN, Kubo C, Koga Y. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J Physiol 2004; 558: 263-275 [PMID: 15133062 DOI: 10.1113/jphysiol.2004.063388]
127. Neufeld KM, Kang N, Bienenstock J, Foster JA. Reduced anxietylike behavior and central neurochemical change in germ-free mice. Neurogastroenterol Motil 2011; 23: 255-264, e119 [PMID: 21054680 DOI: 10.1111/j.1365-2982.2010.01620.x]
128. Messaoudi M, Lalonde R, Violle N, Javelot H, Desor D, Nejdi A, Bisson JF, Rougeot C, Pichelin M, Cazaubiel M, Cazaubiel JM. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br J Nutr 2011; 105: 755-764 [PMID: 20974015 DOI: 10.1017/S0007114510004319]
129. Koloski NA, Jones M, Kalantar J, Weltman M, Zaguirre J, Talley NJ. The brain-gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut 2012; 61: 1284-1290 [PMID: 22234979 DOI: 10.1136/gutjnl-2011-300474]
130. Mayer EA, Savidge T, Shulman RJ. Brain-gut microbiome interactions and functional bowel disorders. Gastroenterology 2014; 146: 1500-1512 [PMID: 24583088 DOI: 10.1053/j.gastro.2014.02.037]
131. Wells JM, Rossi O, Meijerink M, van Baarlen P. Epithelial crosstalk at the microbiota-mucosal interface. Proc Natl Acad Sci USA 2011; 108 Suppl 1: 4607-4614 [PMID: 20826446 DOI: 10.1073/pnas.1000092107]
132. Jenkins DG, Quigley BM. The y-intercept of the critical power function as a measure of anaerobic work capacity. Ergonomics 1991; 34: 13-22 [PMID: 2009846 DOI: 10.1038/nri2707]
133. Ostaff MJ, Stange EF, Wehkamp J. Antimicrobial peptides and gut microbiota in homeostasis and pathology. EMBO Mol Med 2013; 5: 1465-1483 [PMID: 24039130 DOI: 10.1002/emmm.201201773]
134. McClure R, Massari P. TLR-Dependent Human Mucosal Epithelial Cell Responses to Microbial Pathogens. Front Immunol 2014; 5: 386 [PMID: 25161655 DOI: 10.3389/fimmu.2014.00386]
135. Perez-Chanona E, Mühlbauer M, Jobin C. The microbiota protects against ischemia/reperfusion-induced intestinal injury through nucleotide-binDing oligomerization domain-containing protein 2 (NOD2) signaling. Am J Pathol 2014; 184: 2965-2975 [PMID: 25204845 DOI: 10.1016/j.ajpath.2014.07.014]
136. Davies JM, Abreu MT. Host-microbe interactions in the small bowel. Curr Opin Gastroenterol 2015; 31: 118-123 [PMID: 25426971 DOI: 10.1097/MOG.0000000000000143]
137. Murata K, Tomosada Y, Villena J, Chiba E, Shimazu T, Aso H, Iwabuchi N, Xiao JZ, Saito T, Kitazawa H. Bifidobacterium breve MCC-117 Induces Tolerance in Porcine Intestinal Epithelial Cells: Study of the Mechanisms Involved in the Immunoregulatory Effect. Biosci Microbiota Food Health 2014; 33: 1-10 [PMID: 24936377 DOI: 10.12938/bmfh.33.1]
138. McDermott AJ, Huffnagle GB. The microbiome and regulation of mucosal immunity. Immunology 2014; 142: 24-31 [PMID: 24329495 DOI: 10.1111/imm.12231]
139. Mu C, Yang Y, Zhu W. Crosstalk Between The Immune Receptors and Gut Microbiota. Curr Protein Pept Sci 2015; 16: 622-631 [PMID: 26122782]
140. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014; 11: 506-514 [PMID: 24912386 DOI: 10.1038/nrgastro.2014.66]
141. Food and Agriculture Organization/World Health Organization. Evaluation of health and nutritional properties of probiotics in food, incluDing powder milk with the live lactic acid bacteria. Report of a Joint FAO/WHO Expert Consultation on evaluation of health and nutritional properties of probiotics in food incluDing powder milk with live lactic acid bacteria. Available from: URL: http://www.who.int/foodsafety/publications/fs-management/en/probiotics.pdf
142. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, Quigley EM. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010; 59: 325-332 [PMID: 19091823 DOI: 10.1136/gut.2008.167270]
143. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, doubleblind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001; 13: 1143-1147 [PMID: 11711768]
144. Nobaek S, Johansson ML, Molin G, Ahrné S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95: 1231-1238 [PMID: 10811333 DOI: 10.1111/j.1572-0241.2000.02015.x]
145. Sinn DH, Song JH, Kim HJ, Lee JH, Son HJ, Chang DK, Kim YH, Kim JJ, Rhee JC, Rhee PL. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci 2008; 53: 2714-2718 [PMID: 18274900 DOI: 10.1007/s10620-007-0196-4]
146. Long ZR, Yu CH, Yang Y, Wang HN, Chi XX. [Clinical observation on acupuncture combined with microorganism pharmaceutical preparations for treatment of irritable bowel syndrome of constipation type]. Zhongguo Zhenjiu 2006; 26: 403-405 [PMID: 16813181]
147. Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O' Mahony L, Kiely B, Shanahan F, Quigley EM. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101: 1581-1590 [PMID: 16863564 DOI: 10.1111/j.1572-0241.2006.00734. x]
148. Gade J, Thorn P. Paraghurt for patients with irritable bowel syndrome. A controlled clinical investigation from general practice. Scand J Prim Health Care 1989; 7: 23-26 [PMID: 2657953]
149. Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thomforde GM, Zinsmeister AR. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17: 895-904 [PMID: 12656692 DOI: 10.1046/j.1365-2036.2003.01543.x]
150. Kajander K, Hatakka K, Poussa T, Färkkilä M, Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 2005; 22: 387-394 [PMID: 16128676 DOI: 10.1111/j.1365-2036.2005.02579.x]
151. Lorenzo-Zúñiga V, Llop E, Suárez C, Alvarez B, Abreu L, Espadaler J, Serra J. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World J Gastroenterol 2014; 20: 8709-8716 [PMID: 25024629 DOI: 10.3748/wjg.v20.i26.8709]
152. Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol Clin Biol 2008; 32: 147-152 [PMID: 18387426 DOI: 10.1016/j.gcb.2007.06.001]
153. Clarke G, Cryan JF, Dinan TG, Quigley EM. Review article: probiotics for the treatment of irritable bowel syndrome-focus on lactic acid bacteria. Aliment Pharmacol Ther 2012; 35: 403-413 [PMID: 22225517 DOI: 10.1111/j.1365-2036.2011.04965.x]
154. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-551 [PMID: 15765388 DOI: 10.1053/j.gastro.2004.11.050]
155. Guglielmetti S, Mora D, Gschwender M, Popp K. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life-a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2011; 33: 1123-1132 [PMID: 21418261 DOI: 10.1111/j.1365-2036.2011.04633.x]
156. Agrawal A, Houghton LA, Morris J, Reilly B, Guyonnet D, Goupil Feuillerat N, Schlumberger A, Jakob S, Whorwell PJ. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2009; 29: 104-114 [PMID: 18801055 DOI: 10.1111/j.1365-2036.2008.03853.x]
157. Guyonnet D, Chassany O, Ducrotte P, Picard C, Mouret M, Mercier CH, Matuchansky C. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the healthrelated quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007; 26: 475-486 [PMID: 17635382 DOI: 10.1111/j.1365-2036.2007.03362.x]
158. Andriulli A, Neri M, Loguercio C, Terreni N, Merla A, Cardarella MP, Federico A, Chilovi F, Milandri GL, De Bona M, Cavenati S, Gullini S, Abbiati R, Garbagna N, Cerutti R, Grossi E. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized study. J Clin Gastroenterol 2008; 42 Suppl 3 Pt 2: S218-S223 [PMID: 18685503 DOI: 10.1097/MCG.0b013e31817fadd6]
159. Lönnermark E, Friman V, Lappas G, Sandberg T, Berggren A, Adlerberth I. Intake of Lactobacillus plantarum reduces certain gastrointestinal symptoms during treatment with antibiotics. J Clin Gastroenterol 2010; 44: 106-112 [PMID: 19727002 DOI: 10.1097/MCG.0b013e3181b2683f]
160. Gawro?ska A, Dziechciarz P, Horvath A, Szajewska H. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther 2007; 25: 177-184 [PMID: 17229242 DOI: 10.1111/j.1365-2036.2006.03175.x]
161. Francavilla R, Miniello V, Magistà AM, De Canio A, Bucci N, Gagliardi F, Lionetti E, Castellaneta S, Polimeno L, Peccarisi L, Indrio F, Cavallo L. A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain. Pediatrics 2010; 126: e1445-e1452 [PMID: 21078735 DOI: 10.1542/peds.2010-0467]
162. Bauserman M, Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr 2005; 147: 197-201 [PMID: 16126049 DOI: 10.1016/j.jpeds.2005.05.015]
163. Horvath A, Dziechciarz P, Szajewska H. Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood. Aliment Pharmacol Ther 2011; 33: 1302-1310 [PMID: 21507030 DOI: 10.1111/j.1365-2036.2011.04665.x]
164. O'Sullivan MA, O'Morain CA. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebocontrolled crossover study. Dig Liver Dis 2000; 32: 294-301 [PMID: 11515626]
165. Stevenson C, Blaauw R, Fredericks E, Visser J, Roux S. Randomized clinical trial: effect of Lactobacillus plantarum 299 v on symptoms of irritable bowel syndrome. Nutrition 2014; 30: 1151-1157 [PMID: 25194614 DOI: 10.1016/j.nut.2014.02.010]
166. Enck P, Zimmermann K, Menke G, Müller-Lissner S, Martens U, Klosterhalfen S. A mixture of Escherichia coli (DSM 17252) and Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome-a randomized controlled trial with primary care physicians. Neurogastroenterol Motil 2008; 20: 1103-1109 [PMID: 18565142 DOI: 10.1111/j.1365-2982.2008.01156.x]
167. Guandalini S, Magazz G, Chiaro A, La Balestra V, Di Nardo G, Gopalan S, Sibal A, Romano C, Canani RB, Lionetti P, Setty M. VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, doubleblind, crossover study. J Pediatr Gastroenterol Nutr 2010; 51: 24-30 [PMID: 20453678 DOI: 10.1097/MPG.0b013e3181ca4d95]
168. Kim HJ, Vazquez Roque MI, Camilleri M, Stephens D, Burton DD, Baxter K, Thomforde G, Zinsmeister AR. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005; 17: 687-696 [PMID: 16185307 DOI: 10.1111/j.1365-2982.2005.00695.x]
169. Williams EA, Stimpson J, Wang D, Plummer S, Garaiova I, Barker ME, Corfe BM. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther 2009; 29: 97-103 [PMID: 18785988 DOI: 10.1111/j.1365-2036.2008.03848.x]
170. Simrén M, Ohman L, Olsson J, Svensson U, Ohlson K, Posserud I, Strid H. Clinical trial: the effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome-a randomized, double-blind, controlled study. Aliment Pharmacol Ther 2010; 31: 218-227 [PMID: 19863495 DOI: 10.1111/j.1365-2036.2009.04183.x]
171. Lyra A, Krogius-Kurikka L, Nikkilä J, Malinen E, Kajander K, Kurikka K, Korpela R, Palva A. Effect of a multispecies probiotic supplement on quantity of irritable bowel syndrome-related intestinal microbial phylotypes. BMC Gastroenterol 2010; 10: 110 [PMID: 20849659 DOI: 10.1186/1471-230X-10-110]
172. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2009; 104: 1033-1049; quiz 1050 [PMID: 19277023 DOI: 10.1038/ajg.2009.25]
173. Hungin AP, Mulligan C, Pot B, Whorwell P, Agréus L, Fracasso P, Lionis C, Mendive J, Philippart de Foy JM, Rubin G, Winchester C, de Wit N. Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice-an evidencebased international guide. Aliment Pharmacol Ther 2013; 38: 864-886 [PMID: 23981066 DOI: 10.1111/apt.12460]
174. Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, Hyuk J, Kyung Chang S, Kim K, Chung WS, Seo JG. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Gastroenterol 2012; 46: 220-227 [PMID: 22157240 DOI: 10.1097/MCG.0b013e31823712b1]
175. Zeng J, Li YQ, Zuo XL, Zhen YB, Yang J, Liu CH. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2008; 28: 994-1002 [PMID: 18671775 DOI: 10.1111/j.1365-2036.2008.03818.x]
176. Enck P, Zimmermann K, Menke G, Klosterhalfen S. Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E.-coli preparation (DSM17252) compared to placebo. Z Gastroenterol 2009; 47: 209-214 [PMID: 19197823 DOI: 10.1055/s-2008-1027702]
177. Søndergaard B, Olsson J, Ohlson K, Svensson U, Bytzer P, Ekesbo R. Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: a randomized, placebo-controlled trial. Scand J Gastroenterol 2011; 46: 663-672 [PMID: 21443416 DOI: 10.3109/00365521.2011.565 066]
178. Sen S, Mullan MM, Parker TJ, Woolner JT, Tarry SA, Hunter JO. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002; 47: 2615-2620 [PMID: 12452404]
179. Kajander K, Myllyluoma E, RajiliStojanovi? M, Kyrönpalo S, Rasmussen M, Järvenpää S, Zoetendal EG, de Vos WM, Vapaatalo H, Korpela R. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther 2008; 27: 48-57 [PMID: 17919270 DOI: 10.1111/j.1365-2036.2007.03542.x]
180. Guyonnet D, Schlumberger A, Mhamdi L, Jakob S, Chassany O. Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms: a randomised, double-blind, parallel, controlled study. Br J Nutr 2009; 102: 1654-1662 [PMID: 19622191 DOI: 10.1017/S0007114509990882]
181. Ojetti V, Gigante G, Gabrielli M, Ainora ME, Mannocci A, Lauritano EC, Gasbarrini G, Gasbarrini A. The effect of oral supplementation with Lactobacillus reuteri or tilactase in lactose intolerant patients: randomized trial. Eur Rev Med Pharmacol Sci 2010; 14: 163-170 [PMID: 20391953]
182. Ligaarden SC, Axelsson L, Naterstad K, Lydersen S, Farup PG. A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial. BMC Gastroenterol 2010; 10: 16 [PMID: 20144246 DOI: 10.1186/1471-230X-10-16]
183. S Kim L, Hilli L, Orlowski J, Kupperman JL, Baral M, F Waters R. Efficacy of probiotics and nutrients in functional gastrointestinal disorders: a preliminary clinical trial. Dig Dis Sci 2006; 51: 2134-2144 [PMID: 17078006]
184. Hong KS, Kang HW, Im JP, Ji GE, Kim SG, Jung HC, Song IS, Kim JS. Effect of probiotics on symptoms in korean adults with irritable bowel syndrome. Gut Liver 2009; 3: 101-107 [PMID: 20431731 DOI: 10.5009/gnl.2009.3.2.101]
185. Waller PA, Gopal PK, Leyer GJ, Ouwehand AC, Reifer C, Stewart ME, Miller LE. Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. Scand J Gastroenterol 2011; 46: 1057-1064 [PMID: 21663486 DOI: 10.3109/00365521.2011.584895]
186. Kalman DS, Schwartz HI, Alvarez P, Feldman S, Pezzullo JC, Krieger DR. A prospective, randomized, double-blind, placebocontrolled parallel-group dual site trial to evaluate the effects of a Bacillus coagulans-based product on functional intestinal gas symptoms. BMC Gastroenterol 2009; 9: 85 [PMID: 19922649 DOI: 10.1186/1471-230X-9-85]
187. Pitkala KH, Strandberg TE, Finne Soveri UH, Ouwehand AC, Poussa T, Salminen S. Fermented cereal with specific bifidobacteria normalizes bowel movements in elderly nursing home residents. A randomized, controlled trial. J Nutr Health Aging 2007; 11: 305-311 [PMID: 17653486]
188. Larsen CN, Nielsen S, Kaestel P, Brockmann E, Bennedsen M, Christensen HR, Eskesen DC, Jacobsen BL, Michaelsen KF. Doseresponse study of probiotic bacteria Bifidobacterium animalis subsp lactis BB-12 and Lactobacillus paracasei subsp paracasei CRL-341 in healthy young adults. Eur J Clin Nutr 2006; 60: 1284-1293 [PMID: 16721394 DOI: 10.1038/sj.ejcn.1602450]
189. Didari T, Mozaffari S, Nikfar S, Abdollahi M. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. World J Gastroenterol 2015; 21: 3072-3084 [PMID: 25780308 DOI: 10.3748/wjg.v21.i10.3072]
190. Kruis W, Chrubasik S, Boehm S, Stange C, Schulze J. A doubleblind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome. Int J Colorectal Dis 2012; 27: 467-474 [PMID: 22130826 DOI: 10.1007/s00384-011-1363-9]
191. Ducrotté P, Sawant P, Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol 2012; 18: 4012-4018 [PMID: 22912552 DOI: 10.3748/wjg.v18.i30.4012]
192. Roberts LM, McCahon D, Holder R, Wilson S, Hobbs FD. A randomised controlled trial of a probiotic 'functional food' in the management of irritable bowel syndrome. BMC Gastroenterol 2013; 13: 45 [PMID: 23496803 DOI: 10.1186/1471-230X-13-45]
193. Dapoigny M, Piche T, Ducrotte P, Lunaud B, Cardot JM, Bernalier-Donadille A. Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: a randomized, double-blind study. World J Gastroenterol 2012; 18: 2067-2075 [PMID: 22563194 DOI: 10.3748/wjg.v18.i17.2067]
194. Hun L. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgrad Med 2009; 121: 119-124 [PMID: 19332970 DOI: 10.3810/pgm.2009.03.1984]
195. Dolin BJ. Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. Methods Find Exp Clin Pharmacol 2009; 31: 655-659 [PMID: 20140275 DOI: 10.1358/mf.2009.31.10.1441078]
196. Hong YS, Hong KS, Park MH, Ahn YT, Lee JH, Huh CS, Lee J, Kim IK, Hwang GS, Kim JS. Metabonomic understanDing of probiotic effects in humans with irritable bowel syndrome. J Clin Gastroenterol 2011; 45: 415-425 [PMID: 21494186 DOI: 10.1097/MCG.0b013e318207f76c]
197. Choi CH, Jo SY, Park HJ, Chang SK, Byeon JS, Myung SJ. A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroenterol 2011; 45: 679-683 [PMID: 21301358 DOI: 10.1097/MCG.0b013e318204593e]
198. Michail S, Kenche H. Gut microbiota is not modified by Randomized, Double-blind, Placebo-controlled Trial of VSL#3 in Diarrhea-predominant Irritable Bowel Syndrome. Probiotics Antimicrob Proteins 2011; 3: 1-7 [PMID: 22247743 DOI: 10.1007/s12602-010-9059-y]
199. Brigidi P, Vitali B, Swennen E, Bazzocchi G, Matteuzzi D. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res Microbiol 2001; 152: 735-741 [PMID: 11686387 DOI: 10.1016/S0923-2508(01)01254-2]
200. Gibson GR, Wang X. Regulatory effects of bifidobacteria on the growth of other colonic bacteria. J Appl Bacteriol 1994; 77: 412-420 [PMID: 7989269]
201. Liévin V, Peiffer I, Hudault S, Rochat F, Brassart D, Neeser JR, Servin AL. Bifidobacterium strains from resident infant human gastrointestinal microflora exert antimicrobial activity. Gut 2000; 47: 646-652 [PMID: 11034580 DOI: 10.1136/gut.47.5.646]
202. Mattar AF, Teitelbaum DH, Drongowski RA, Yongyi F, Harmon CM, Coran AG. Probiotics up-regulate MUC-2 mucin gene expression in a Caco-2 cell-culture model. Pediatr Surg Int 2002; 18: 586-590 [PMID: 12471471]
203. Kim Y, Kim SH, Whang KY, Kim YJ, Oh S. Inhibition of Escherichia coli O157: H7 attachment by interactions between lactic acid bacteria and intestinal epithelial cells. J Microbiol Biotechnol 2008; 18: 1278-1285 [PMID: 18667857]
204. Da Silva S, Robbe-Masselot C, Ait-Belgnaoui A, Mancuso A, Mercade-Loubière M, Salvador-Cartier C, Gillet M, Ferrier L, Loubière P, Dague E, Theodorou V, Mercier-Bonin M. Stress disrupts intestinal mucus barrier in rats via mucin O-glycosylation shift: prevention by a probiotic treatment. Am J Physiol Gastrointest Liver Physiol 2014; 307: G420-G429 [PMID: 24970779 DOI: 10.1152/ajpgi.00290.2013]
205. Snape WJ, Carlson GM, Cohen S. Colonic myoelectric activity in the irritable bowel syndrome. Gastroenterology 1976; 70: 326-330 [PMID: 765183]
206. Whitehead WE, Engel BT, Schuster MM. Irritable bowel syndrome: physiological and psychological differences between diarrhea-predominant and constipation-predominant patients. Dig Dis Sci 1980; 25: 404-413 [PMID: 7379673]
207. Ansari R, Sohrabi S, Ghanaie O, Amjadi H, Merat S, Vahedi H, Khatibian M. Comparison of colonic transit time between patients with constipation-predominant irritable bowel syndrome and functional constipation. Indian J Gastroenterol 2010; 29: 66-68 [PMID: 20443103 DOI: 10.1007/s12664-010-0015-2]
208. Serra J, Azpiroz F, Malagelada JR. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut 2001; 48: 14-19 [PMID: 11115817]
209. Miller LE, Ouwehand AC. Probiotic supplementation decreases intestinal transit time: meta-analysis of randomized controlled trials. World J Gastroenterol 2013; 19: 4718-4725 [PMID: 23922468 DOI: 10.3748/wjg.v19.i29.4718]
210. Dimidi E, Christodoulides S, Fragkos KC, Scott SM, Whelan K. The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr 2014; 100: 1075-1084 [PMID: 25099542 DOI: 10.3945/ajcn.114.089151]
211. Eskesen D, Jespersen L, Michelsen B, Whorwell PJ, Müller-Lissner S, Morberg CM. Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebocontrolled, parallel-group trial. Br J Nutr 2015; 114: 1638-1646 [PMID: 26382580 DOI: 10.1017/S0007114515003347]
212. Choi CH, Kwon JG, Kim SK, Myung SJ, Park KS, Sohn CI, Rhee PL, Lee KJ, Lee OY, Jung HK, Jee SR, Jeen YT, Choi MG, Choi SC, Huh KC, Park H. Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial. Neurogastroenterol Motil 2015; 27: 705-716 [PMID: 25809913 DOI: 10.1111/nmo.12544]
213. Johnson AC, Greenwood-Van Meerveld B, McRorie J. Effects of Bifidobacterium infantis 35624 on post-inflammatory visceral hypersensitivity in the rat. Dig Dis Sci 2011; 56: 3179-3186 [PMID: 21562785 DOI: 10.1007/s10620-011-1730-y]
214. Distrutti E, Cipriani S, Mencarelli A, Renga B, Fiorucci S. Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome. PLoS One 2013; 8: e63893 [PMID: 23691109 DOI: 10.1371/journal.pone.0063893]
215. Bercik P, Denou E, Collins J, Jackson W, Lu J, Jury J, Deng Y, Blennerhassett P, Macri J, McCoy KD, Verdu EF, Collins SM. The intestinal microbiota affect central levels of brainderived neurotropic factor and behavior in mice. Gastroenterology 2011; 141: 599-609, 609.e1-e3 [PMID: 21683077 DOI: 10.1053/j.gastro.2011.04.052]
216. Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, Bienenstock J, Cryan JF. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci USA 2011; 108: 16050-16055 [PMID: 21876150 DOI: 10.1073/pnas.1102999108]
217. Ludidi S, Jonkers DM, Koning CJ, Kruimel JW, Mulder L, van der Vaart IB, Conchillo JM, Masclee AA. Randomized clinical trial on the effect of a multispecies probiotic on visceroperception in hypersensitive IBS patients. Neurogastroenterol Motil 2014; 26: 705-714 [PMID: 24588932 DOI: 10.1111/nmo.12320]
218. Ohman L, Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010; 7: 163-173 [PMID: 20101257 DOI: 10.1038/nrgastro.2010.4]
219. Bashashati M, Rezaei N, Bashashati H, Shafieyoun A, Daryani NE, Sharkey KA, Storr M. Cytokine gene polymorphisms are associated with irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterol Motil 2012; 24: 1102-e566 [PMID: 22897390 DOI: 10.1111/j.1365-2982.2012.01990.x]
220. Hughes PA, Zola H, Penttila IA, Blackshaw LA, Andrews JM, Krumbiegel D. Immune activation in irritable bowel syndrome: can neuroimmune interactions explain symptoms? Am J Gastroenterol 2013; 108: 1066-1074 [PMID: 23649183 DOI: 10.1038/ajg.2013.120]
221. Martín R, Chain F, Miquel S, Natividad JM, Sokol H, Verdu EF, Langella P, Bermúdez-Humarán LG. Effects in the use of a genetically engineered strain of Lactococcus lactis delivering in situ IL-10 as a therapy to treat low-grade colon inflammation. Hum Vaccin Immunother 2014; 10: 1611-1621 [PMID: 24732667 DOI: 10.4161/hv.28549]
222. Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, Doyle J, Jewell L, De Simone C. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001; 121: 580-591 [PMID: 11522742]
223. Shi CZ, Chen HQ, Liang Y, Xia Y, Yang YZ, Yang J, Zhang JD, Wang SH, Liu J, Qin HL. Combined probiotic bacteria promotes intestinal epithelial barrier function in interleukin-10-genedeficient mice. World J Gastroenterol 2014; 20: 4636-4647 [PMID: 24782616 DOI: 10.3748/wjg.v20.i16.4636]
224. Nébot-Vivinus M, Harkat C, Bzioueche H, Cartier C, Plichon-Dainese R, Moussa L, Eutamene H, Pishvaie D, Holowacz S, Seyrig C, Piche T, Theodorou V. Multispecies probiotic protects gut barrier function in experimental models. World J Gastroenterol 2014; 20: 6832-6843 [PMID: 24944474 DOI: 10.3748/wjg.v20. i22.6832]
225. Laval L, Martin R, Natividad JN, Chain F, Miquel S, Desclée de Maredsous C, Capronnier S, Sokol H, Verdu EF, van Hylckama Vlieg JE, Bermúdez-Humarán LG, Smokvina T, Langella P. Lactobacillus rhamnosus CNCM I-3690 and the commensal bacterium Faecalibacterium prausnitzii A2-165 exhibit similar protective effects to induced barrier hyper-permeability in mice. Gut Microbes 2015; 6: 1-9 [PMID: 25517879 DOI: 10.4161/19490 976.2014.990784]
226. Pagnini C, Saeed R, Bamias G, Arseneau KO, Pizarro TT, Cominelli F. Probiotics promote gut health through stimulation of epithelial innate immunity. Proc Natl Acad Sci USA 2010; 107: 454-459 [PMID: 20018654 DOI: 10.1073/pnas.0910307107]
227. Hart AL, Lammers K, Brigidi P, Vitali B, Rizzello F, Gionchetti P, Campieri M, Kamm MA, Knight SC, Stagg AJ. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut 2004; 53: 1602-1609 [PMID: 15479680 DOI: 10.1136/gut.2003.037325]
228. Rodes L, Khan A, Paul A, Coussa-Charley M, Marinescu D, Tomaro-Duchesneau C, Shao W, Kahouli I, Prakash S. Effect of probiotics Lactobacillus and Bifidobacterium on gut-derived lipopolysaccharides and inflammatory cytokines: an in vitro study using a human colonic microbiota model. J Microbiol Biotechnol 2013; 23: 518-526 [PMID: 23568206]
229. Urbanska AM, Paul A, Bhathena J, Prakash S. Suppression of tumorigenesis: modulation of inflammatory cytokines by oral administration of microencapsulated probiotic yogurt formulation. Int J Inflam 2010; 2010: 894972 [PMID: 21188222 DOI: 10.4061/2010/894972]
230. Barouei J, Moussavi M, Hodgson DM. Perinatal maternal probiotic intervention impacts immune responses and ileal mucin gene expression in a rat model of irritable bowel syndrome. Benef Microbes 2015; 6: 83-95 [PMID: 25245571 DOI: 10.3920/BM2013.0011]
231. Spaiser SJ, Culpepper T, Nieves C, Ukhanova M, Mai V, Percival SS, Christman MC, Langkamp-Henken B. Lactobacillus gasseri KS-13, Bifidobacterium bifidum G9-1, and Bifidobacterium longum MM-2 Ingestion Induces a Less Inflammatory Cytokine Profile and a Potentially Beneficial Shift in Gut Microbiota in Older Adults: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study. J Am Coll Nutr 2015; 34: 459-469 [PMID: 25909149 DOI: 10.1080/07315724.2014.983249]
232. Abbas Z, Yakoob J, Jafri W, Ahmad Z, Azam Z, Usman MW, Shamim S, Islam M. Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial. Eur J Gastroenterol Hepatol 2014; 26: 630-639 [PMID: 24722560 DOI: 10.1097/MEG.0000000000000094]
233. Boren J, Lee WN, Bassilian S, Centelles JJ, Lim S, Ahmed S, Boros LG, Cascante M. The stable isotope-based dynamic metabolic profile of butyrate-induced HT29 cell differentiation. J Biol Chem 2003; 278: 28395-28402 [PMID: 12750369 DOI: 10.1074/jbc.M302932200]
234. Ogawa H, Rafiee P, Fisher PJ, Johnson NA, Otterson MF, Binion DG. Butyrate modulates gene and protein expression in human intestinal endothelial cells. Biochem Biophys Res Commun 2003; 309: 512-519 [PMID: 12963019 DOI: 10.1016/j.bbrc.2003.08.026]
235. Gaudier E, Jarry A, Blottière HM, de Coppet P, Buisine MP, Aubert JP, Laboisse C, Cherbut C, Hoebler C. Butyrate specifically modulates MUC gene expression in intestinal epithelial goblet cells deprived of glucose. Am J Physiol Gastrointest Liver Physiol 2004; 287: G1168-G1174 [PMID: 15308471 DOI: 10.1152/ajpgi.00219.2004]
236. Roediger WE. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut 1980; 21: 793-798 [PMID: 7429343]
237. McIntyre A, Gibson PR, Young GP. Butyrate production from dietary fibre and protection against large bowel cancer in a rat model. Gut 1993; 34: 386-391 [PMID: 8386131]
238. Vanhoutvin SA, Troost FJ, Kilkens TO, Lindsey PJ, Hamer HM, Jonkers DM, Venema K, Brummer RJ. The effects of butyrate enemas on visceral perception in healthy volunteers. Neurogastroenterol Motil 2009; 21: 952-e76 [PMID: 19460106 DOI: 10.1111/j.1365-2982.2009.01324.x]
239. Fukumoto S, Tatewaki M, Yamada T, Fujimiya M, Mantyh C, Voss M, Eubanks S, Harris M, Pappas TN, Takahashi T. Shortchain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats. Am J Physiol Regul Integr Comp Physiol 2003; 284: R1269-R1276 [PMID: 12676748 DOI: 10.1152/ajpregu.00442.2002]
240. Treem WR, Ahsan N, Kastoff G, Hyams JS. Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation. J Pediatr Gastroenterol Nutr 1996; 23: 280-286 [PMID: 8890079]
241. Ferrario C, Taverniti V, Milani C, Fiore W, Laureati M, De Noni I, Stuknyte M, Chouaia B, Riso P, Guglielmetti S. Modulation of fecal Clostridiales bacteria and butyrate by probiotic intervention with Lactobacillus paracasei DG varies among healthy adults. J Nutr 2014; 144: 1787-1796 [PMID: 25332478 DOI: 10.3945/jn.114.197723]
242. Kato K, Mizuno S, Umesaki Y, Ishii Y, Sugitani M, Imaoka A, Otsuka M, Hasunuma O, Kurihara R, Iwasaki A, Arakawa Y. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 2004; 20: 1133-1141 [PMID: 15569116 DOI: 10.1111/j.1365-2036.2004.02268.x]
243. Mohan R, Koebnick C, Schildt J, Mueller M, Radke M, Blaut M. Effects of Bifidobacterium lactis Bb12 supplementation on body weight, fecal pH, acetate, lactate, calprotectin, and IgA in preterm infants. Pediatr Res 2008; 64: 418-422 [PMID: 18552710 DOI: 10.1203/PDR.0b013e318181b7fa]
244. Dinan TG, Quigley EM, Ahmed SM, Scully P, O'Brien S, O' Mahony L, O'Mahony S, Shanahan F, Keeling PW. Hypothalamicpituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006; 130: 304-311 [PMID: 16472586 DOI: 10.1053/j.gastro.2005.11.033]
245. Kennedy PJ, Cryan JF, Quigley EM, Dinan TG, Clarke G. A sustained hypothalamic-pituitary-adrenal axis response to acute psychosocial stress in irritable bowel syndrome. Psychol Med 2014; 44: 3123-3134 [PMID: 25065954 DOI: 10.1017/S003329171400052X]
246. Barouei J, Moussavi M, Hodgson DM. Effect of maternal probiotic intervention on HPA axis, immunity and gut microbiota in a rat model of irritable bowel syndrome. PLoS One 2012; 7: e46051 [PMID: 23071537 DOI: 10.1371/journal.pone.0046051]
247. Gareau MG, Jury J, MacQueen G, Sherman PM, Perdue MH. Probiotic treatment of rat pups normalises corticosterone release and ameliorates colonic dysfunction induced by maternal separation. Gut 2007; 56: 1522-1528 [PMID: 17339238 DOI: 10.1136/gut.2006.117176]
248. Savignac HM, Tramullas M, Kiely B, Dinan TG, Cryan JF. Bifidobacteria modulate cognitive processes in an anxious mouse strain. Behav Brain Res 2015; 287: 59-72 [PMID: 25794930 DOI: 10.1016/j.bbr.2015.02.044]
249. Distrutti E, O'Reilly JA, McDonald C, Cipriani S, Renga B, Lynch MA, Fiorucci S. Modulation of intestinal microbiota by the probiotic VSL#3 resets brain gene expression and ameliorates the age-related deficit in LTP. PLoS One 2014; 9: e106503 [PMID: 25202975 DOI: 10.1371/journal.pone.0106503]
250. O'Sullivan E, Barrett E, Grenham S, Fitzgerald P, Stanton C, Ross RP, Quigley EM, Cryan JF, Dinan TG. BDNF expression in the hippocampus of maternally separated rats: does Bifidobacterium breve 6330 alter BDNF levels? Benef Microbes 2011; 2: 199-207 [PMID: 21986359 DOI: 10.3920/BM2011.0015]
251. Pineiro M, Asp NG, Reid G, Macfarlane S, Morelli L, Brunser O, Tuohy K. FAO Technical meeting on prebiotics. J Clin Gastroenterol 2008; 42 Suppl 3 Pt 2: S156-S159 [PMID: 18685504 DOI: 10.1097/MCG.0b013e31817f184e]
252. Roberfroid MB. Functional foods: concepts and application to inulin and oligofructose. Br J Nutr 2002; 87 Suppl 2: S139-S143 [PMID: 12088510 DOI: 10.1079/BJN/2002529]
253. Boehm G, Stahl B, Jelinek J, Knol J, Miniello V, Moro GE. Prebiotic carbohydrates in human milk and formulas. Acta Paediatr Suppl 2005; 94: 18-21 [PMID: 16214760]
254. Chatchatee P, Lee WS, Carrilho E, Kosuwon P, Simakachorn N, Yavuz Y, Schouten B, Graaff PL, Szajewska H. Effects of growingup milk supplemented with prebiotics and LCPUFAs on infections in young children. J Pediatr Gastroenterol Nutr 2014; 58: 428-437 [PMID: 24614142 DOI: 10.1097/MPG.0000000000000252]
255. Neyrinck AM, Van Hée VF, Bindels LB, De Backer F, Cani PD, Delzenne NM. Polyphenol-rich extract of pomegranate peel alleviates tissue inflammation and hypercholesterolaemia in highfat diet-induced obese mice: potential implication of the gut microbiota. Br J Nutr 2013; 109: 802-809 [PMID: 22676910 DOI: 10.1017/S0007114512002206]
256. Yasuda A, Inoue K, Sanbongi C, Yanagisawa R, Ichinose T, Tanaka M, Yoshikawa T, Takano H. Dietary supplementation with fructooligosaccharides attenuates allergic peritonitis in mice. Biochem Biophys Res Commun 2012; 422: 546-550 [PMID: 22580001 DOI: 10.1016/j.bbrc.2012.05.007]
257. Arslanoglu S, Moro GE, Boehm G, Wienz F, Stahl B, Bertino E. Early neutral prebiotic oligosaccharide supplementation reduces the incidence of some allergic manifestations in the first 5 years of life. J Biol Regul Homeost Agents 2012; 26: 49-59 [PMID: 23158515]
258. Hayen SM, Kostadinova AI, Garssen J, Otten HG, Willemsen LE. Novel immunotherapy approaches to food allergy. Curr Opin Allergy Clin Immunol 2014; 14: 549-556 [PMID: 25159183 DOI: 10.1097/ACI.0000000000000109]
259. Dasopoulou M, Briana DD, Boutsikou T, Karakasidou E, Roma E, Costalos C, Malamitsi-Puchner A. Motilin and gastrin secretion and lipid profile in preterm neonates following prebiotics supplementation: a double-blind randomized controlled study. JPEN J Parenter Enteral Nutr 2015; 39: 359-368 [PMID: 24233255 DOI: 10.1177/0148607113510182]
260. Armanian AM, Sadeghnia A, Hoseinzadeh M, Mirlohi M, Feizi A, Salehimehr N, Saee N, Nazari J. The Effect of Neutral Oligosaccharides on Reducing the Incidence of Necrotizing Enterocolitis in Preterm infants: A Randomized Clinical Trial. Int J Prev Med 2014; 5: 1387-1395 [PMID: 25538834]
261. Magrone T, Jirillo E. Childhood obesity: immune response and nutritional approaches. Front Immunol 2015; 6: 76 [PMID: 25759691 DOI: 10.3389/fimmu.2015.00076]
262. Mirmiran P, Bahadoran Z, Azizi F. Functional foods-based diet as a novel dietary approach for management of type 2 diabetes and its complications: A review. World J Diabetes 2014; 5: 267-281 [PMID: 24936248 DOI: 10.4239/wjd.v5.i3.267]
263. Romero-Gómez M, Montagnese S, Jalan R. Hepatic encephalopathy in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. J Hepatol 2015; 62: 437-447 [PMID: 25218789 DOI: 10.1016/j.jhep.2014.09.005]
264. Ghouri YA, Richards DM, Rahimi EF, Krill JT, Jelinek KA, DuPont AW. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol 2014; 7: 473-487 [PMID: 25525379 DOI: 10.2147/CEG.S27530]
265. Collado Yurrita L, San Mauro Martín I, Ciudad-Cabañas MJ, Calle-Purón ME, Hernández Cabria M. Effectiveness of inulin intake on indicators of chronic constipation; a meta-analysis of controlled randomized clinical trials. Nutr Hosp 2014; 30: 244-252 [PMID: 25208775 DOI: 10.3305/nh.2014.30.2.7565]
266. Hunter JO, Tuffnell Q, Lee AJ. Controlled trial of oligofructose in the management of irritable bowel syndrome. J Nutr 1999; 129: 1451S-1453S [PMID: 10395619]
267. Olesen M, Gudmand-Hoyer E. Efficacy, safety, and tolerability of fructooligosaccharides in the treatment of irritable bowel syndrome. Am J Clin Nutr 2000; 72: 1570-1575 [PMID: 11101487]
268. Paineau D, Payen F, Panserieu S, Coulombier G, Sobaszek A, Lartigau I, Brabet M, Galmiche JP, Tripodi D, Sacher-Huvelin S, Chapalain V, Zourabichvili O, Respondek F, Wagner A, Bornet FR. The effects of regular consumption of short-chain fructooligosaccharides on digestive comfort of subjects with minor functional bowel disorders. Br J Nutr 2008; 99: 311-318 [PMID: 17697398 DOI: 10.1017/S000711450779894X]
269. Hasler WL. Lactulose breath testing, bacterial overgrowth, and IBS: just a lot of hot air? Gastroenterology 2003; 125: 1898-1900; discussion 1900 [PMID: 14724846 DOI: 10.1053/j.gastro.2003.08.038]
270. Snook J, Shepherd HA. Bran supplementation in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994; 8: 511-514 [PMID: 7865643 DOI: 10.1111/j.1365-2036.1994.tb00323. x]
271. Badiali D, Corazziari E, Habib FI, Tomei E, Bausano G, Magrini P, Anzini F, Torsoli A. Effect of wheat bran in treatment of chronic nonorganic constipation. A double-blind controlled trial. Dig Dis Sci 1995; 40: 349-356 [PMID: 7851201]
272. Nelis GF, Vermeeren MA, Jansen W. Role of fructose-sorbitol malabsorption in the irritable bowel syndrome. Gastroenterology 1990; 99: 1016-1020 [PMID: 2394324]
273. Symons P, Jones MP, Kellow JE. Symptom provocation in irritable bowel syndrome. Effects of differing doses of fructose-sorbitol. Scand J Gastroenterol 1992; 27: 940-944 [PMID: 1455191]
274. Ong DK, Mitchell SB, Barrett JS, Shepherd SJ, Irving PM, Biesiekierski JR, Smith S, Gibson PR, Muir JG. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol 2010; 25: 1366-1373 [PMID: 20659225 DOI: 10.1111/j.1440-1746.2010.06370.x]
275. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 2014; 146: 67-75.e5 [PMID: 24076059 DOI: 10.1053/j.gastro.2013.09.046]
276. Staudacher HM, Lomer MC, Anderson JL, Barrett JS, Muir JG, Irving PM, Whelan K. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr 2012; 142: 1510-1518 [PMID: 22739368 DOI: 10.3945/jn.112.159285]
277. Tuck CJ, Muir JG, Barrett JS, Gibson PR. Fermentable oligosaccharides, disaccharides, monosaccharides and polyols: role in irritable bowel syndrome. Expert Rev Gastroenterol Hepatol 2014; 8: 819-834 [PMID: 24830318 DOI: 10.1586/17474 124.2014.917956]
278. Halmos EP, Christophersen CT, Bird AR, Shepherd SJ, Gibson PR, Muir JG. Diets that differ in their FODMAP content alter the colonic luminal microenvironment. Gut 2015; 64: 93-100 [PMID: 25016597 DOI: 10.1136/gutjnl-2014-307264]
279. Saneian H, Pourmoghaddas Z, Roohafza H, Gholamrezaei A. Synbiotic containing Bacillus coagulans and fructo-oligosaccharides for functional abdominal pain in children. Gastroenterol Hepatol Bed Bench 2015; 8: 56-65 [PMID: 25584177]
280. Tsuchiya J, Barreto R, Okura R, Kawakita S, Fesce E, Marotta F. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin J Dig Dis 2004; 5: 169-174 [PMID: 15612887 DOI: 10.1111/j.1443-9573.2004.00176.x]
281. Rogha M, Esfahani MZ, Zargarzadeh AH. The efficacy of a synbiotic containing Bacillus Coagulans in treatment of irritable bowel syndrome: a randomized placebo-controlled trial. Gastroenterol Hepatol Bed Bench 2014; 7: 156-163 [PMID: 25120896]
282. Bittner AC, Croffut RM, Stranahan MC. Prescript-Assist probiotic-prebiotic treatment for irritable bowel syndrome: a methodologically oriented, 2-week, randomized, placebocontrolled, double-blind clinical study. Clin Ther 2005; 27: 755-761 [PMID: 16117982 DOI: 10.1016/j.clinthera.2005.06.005]
283. Quigley EM. Therapies aimed at the gut microbiota and inflammation: antibiotics, prebiotics, probiotics, synbiotics, antiinflammatory therapies. Gastroenterol Clin North Am 2011; 40: 207-222 [PMID: 21333908 DOI: 10.1016/j.gtc.2010.12.009]
284. Riordan SM, McIver CJ, Walker BM, Duncombe VM, Bolin TD, Thomas MC. The lactulose breath hydrogen test and small intestinal bacterial overgrowth. Am J Gastroenterol 1996; 91: 1795-1803 [PMID: 8792701]
285. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95: 3503-3506 [PMID: 11151884 DOI: 10.1111/j.1572-0241.2000.03368.x]
286. Bratten JR, Spanier J, Jones MP. Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls. Am J Gastroenterol 2008; 103: 958-963 [PMID: 18371134 DOI: 10.1111/j.1572-0241.2008.01785.x]
287. Schmulson M, Bielsa MV, Carmona-Sánchez R, Hernández A, López-Colombo A, López Vidal Y, Peláez-Luna M, Remes-Troche JM, Tamayo JL, Valdovinos MA. Microbiota, gastrointestinal infections, low-grade inflammation, and antibiotic therapy in irritable bowel syndrome: an evidence-based review. Rev Gastroenterol Mex 2014; 79: 96-134 [PMID: 24857420 DOI: 10.1016/j.rgmx.2014.01.004]
288. Rezaie A, Nikfar S, Abdollahi M. The place of antibiotics in management of irritable bowel syndrome: a systematic review and meta-analysis. Arch Med Sci 2010; 6: 49-55 [PMID: 22371720 DOI: 10.5114/aoms.2010.13507]
289. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006; 145: 557-563 [PMID: 17043337 DOI: 10.7326/0003-4819-1 45-8200610170-00004]
290. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22-32 [PMID: 21208106 DOI: 10.1056/NEJMoa1004409]
291. Menees SB, Maneerattannaporn M, Kim HM, Chey WD. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2012; 107: 28-35; quiz 36 [PMID: 22045120 DOI: 10.1038/ajg.2011.355]
292. Schoenfeld P, Pimentel M, Chang L, Lembo A, Chey WD, Yu J, Paterson C, Bortey E, Forbes WP. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2014; 39: 1161-1168 [PMID: 24697851 DOI: 10.1111/apt.12735]
293. Konturek PC, Haziri D, Brzozowski T, Hess T, Heyman S, Kwiecien S, Konturek SJ, Koziel J. Emerging role of fecal microbiota therapy in the treatment of gastrointestinal and extragastrointestinal diseases. J Physiol Pharmacol 2015; 66: 483-491 [PMID: 26348073]
294. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53: 994-1002 [PMID: 22002980 DOI: 10.1093/cid/cir632]
295. Cammarota G, Ianiro G, Gasbarrini A. Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review. J Clin Gastroenterol 2014; 48: 693-702 [PMID: 24440934 DOI: 10.1097/MCG.0000000000000046]
296. Borody TJ, Warren EF, Leis S, Surace R, Ashman O. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 2003; 37: 42-47 [PMID: 12811208]
297. Zhang FM, Wang HG, Wang M, Cui BT, Fan ZN, Ji GZ. Fecal microbiota transplantation for severe enterocolonic fistulizing Crohn's disease. World J Gastroenterol 2013; 19: 7213-7216 [PMID: 24222969 DOI: 10.3748/wjg.v19.i41.7213]
298. Suskind DL, Brittnacher MJ, Wahbeh G, Shaffer ML, Hayden HS, Qin X, Singh N, Damman CJ, Hager KR, Nielson H, Miller SI. Fecal microbial transplant effect on clinical outcomes and fecal microbiome in active Crohn's disease. Inflamm Bowel Dis 2015; 21: 556-563 [PMID: 25647155 DOI: 10.1097/MIB.0000000000000307]
299. Suskind DL, Singh N, Nielson H, Wahbeh G. Fecal microbial transplant via nasogastric tube for active pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr 2015; 60: 27-29 [PMID: 25162366 DOI: 10.1097/MPG.0000000000000544]
300. Vermeire S, Joossens M, Verbeke K, Wang J, Machiels K, Sabino J, Ferrante M, Van Assche G, Rutgeerts P, Raes J. Donor Species Richness Determines Faecal Microbiota Transplantation Success in Inflammatory Bowel Disease. J Crohns Colitis 2015; Epub ahead of print [PMID: 26519463]
301. Kunde S, Pham A, Bonczyk S, Crumb T, Duba M, Conrad H, Cloney D, Kugathasan S. Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. J Pediatr Gastroenterol Nutr 2013; 56: 597-601 [PMID: 23542823 DOI: 10.1097/MPG.0b013e318292fa0d]
302. Landy J, Walker AW, Li JV, Al-Hassi HO, Ronde E, English NR, Mann ER, Bernardo D, McLaughlin SD, Parkhill J, Ciclitira PJ, Clark SK, Knight SC, Hart AL. Variable alterations of the microbiota, without metabolic or immunological change, following faecal microbiota transplantation in patients with chronic pouchitis. Sci Rep 2015; 5: 12955 [PMID: 26264409 DOI: 10.1038/srep12955]
303. Crouzet L, Gaultier E, Del'Homme C, Cartier C, Delmas E, Dapoigny M, Fioramonti J, Bernalier-Donadille A. The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota. Neurogastroenterol Motil 2013; 25: e272-e282 [PMID: 23433203 DOI: 10.1111/nmo.12103]
304. Bakken JS, Borody T, Brandt LJ, Brill JV, Demarco DC, Franzos MA, Kelly C, Khoruts A, Louie T, Martinelli LP, Moore TA, Russell G, Surawicz C. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011; 9: 1044-1049 [PMID: 21871249 DOI: 10.1016/j.cgh.2011.08.014]
305. Borody TJ, George L, Andrews P, Brandl S, Noonan S, Cole P, Hyland L, Morgan A, Maysey J, Moore-Jones D. Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome? Med J Aust 1989; 150: 604 [PMID: 2783214]
306. Borody TJ, Paramsothy S, Agrawal G. Fecal microbiota transplantation: indications, methods, evidence, and future directions. Curr Gastroenterol Rep 2013; 15: 337 [PMID: 23852569 DOI: 10.1007/s11894-013-0337-1]
307. Andrews PJ, Borody TJ. Putting back the bugs: bacterial treatment relieves chronic constipation and symptoms of irritable bowel syndrome. Med J Aust 1993; 159: 633-634 [PMID: 8155121]
308. Pinn DM, Aroniadis OC, Brandt LJ. Is fecal microbiota transplantation the answer for irritable bowel syndrome? A singlecenter experience. Am J Gastroenterol 2014; 109: 1831-1832 [PMID: 25373585 DOI: 10.1038/ajg.2014.295]
309. Borody TJ, Brandt LJ, Paramsothy S. Therapeutic faecal microbiota transplantation: current status and future developments. Curr Opin Gastroenterol 2014; 30: 97-105 [PMID: 24257037 DOI: 10.1097/MOG.0000000000000027]
310. Lo Vecchio A, Cohen MB. Fecal microbiota transplantation for Clostridium difficile infection: benefits and barriers. Curr Opin Gastroenterol 2014; 30: 47-53 [PMID: 24275671 DOI: 10.1097/MOG.0000000000000023]
311. Pinn DM, Aroniadis OC, Brandt LJ. Is fecal microbiota transplantation (FMT) an effective treatment for patients with functional gastrointestinal disorders (FGID)? Neurogastroenterol Motil 2015; 27: 19-29 [PMID: 25424663 DOI: 10.1111/nmo.12479]